Kazakhstan vs Namibia: Average cost of drugs for extensively drug-resistant tuberculosis
Kazakhstan
6,329 constant 2022 US$
in 2023
Namibia
13,642 constant 2022 US$
in 2024
Kazakhstan rank
5th
Namibia rank
2nd
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Kazakhstan
- Namibia
How they compare
Namibia currently reports 13,642 constant 2022 US$ against 6,329 constant 2022 US$ in Kazakhstan, a difference of 7,313 constant 2022 US$.
That makes Namibia's figure about 2.2 times Kazakhstan's.
Across all 5 years both countries report, Namibia has been ahead every year.
Kazakhstan ranks 5th and Namibia ranks 2nd of 56 countries.
Namibia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kazakhstan | Namibia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,830 constant 2022 US$ | 25,350 constant 2022 US$ | 20,520 constant 2022 US$ | Namibia |
| 2020s | 4,806 constant 2022 US$ | 20,226 constant 2022 US$ | 15,420 constant 2022 US$ | Namibia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Kazakhstan or Namibia?
- Namibia, at 13,642 constant 2022 US$ against 6,329 constant 2022 US$ in Kazakhstan as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Kazakhstan and Namibia?
- 7,313 constant 2022 US$, with Namibia ahead.
- How many years of comparable data are there for Kazakhstan and Namibia?
- 5 years are reported by both, from 2019 to 2023.
- How do Kazakhstan and Namibia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Kazakhstan ranks 5th and Namibia ranks 2nd of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.